Pharma major Dr Reddy’s Laboratories has launched Memantine hydrochloride tablets in the US market following an approval from the United States Food & Drug Administration (USFDA).
The tablet is a therapeutic equivalent generic version of Namenda (memantine HCl) tablets, a registered trademark of Merz Pharma GmbH & Co. KGaA. The brand had U.S. sales of approximately $1.4 billion for the most recent twelve months ending in May 2015 according to IMS Health. It is generally indicated in the treatment of Alzheimer’s disease.
Dr Reddy’s Memantine hydrochloride tablets 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets 10 mg are available in bottle count sizes of 60 and 500, the company said in a release issued here on Monday.
The company’s scrip gained 0.44 per cent on the Bombay Stock Exchange on Monday to end at Rs 3,758.75.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.